Immunochemotherapy regimen: G-CHOP (Arm A)

Phase 3

Immunochemotherapy regimen: G-CHOP (Arm A) is one of 41 therapeutic programs targeting Follicular Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Follicular LymphomaActive, not recruiting

Follicular LymphomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

201 competitors in Follicular Lymphoma

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

83 2

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

26 3

Fludara

Sanofi

Phase 3

8 4

Zydelig

Gilead

Phase 3

6 5

Rayos

RRoxane Laboratories

Phase 3

14 6

Kesimpta

Novartis

Phase 3

2 7

Imbruvica

PPharmacyclics LLC.

Phase 3

10 8

Tazverik

EEpizyme, Inc.

Phase 3

7 9

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

5 10

Copiktra

SSecuraBio

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 3Active, not recruiting

Follicular Lymphoma

NCT05058404

Clinical

Trials by Indication[1]

Follicular Lymphoma1 trial

Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma. A Randomized, Open Label, Phase III Study by Fondazione Italiana Linfomi.

Active, not recruiting·FFondazione Italiana Linfomi - ETS·Phase 3·NCT05058404·605 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Immunochemotherapy regimen: G-CHOP (Arm A). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Immunochemotherapy regimen: G-CHOP (Arm A). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Fondazione Italiana Linfomi - ETS company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: FFondazione Italiana Linfomi - ETS

Immunochemotherapy regimen: G-CHOP (Arm A)

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Follicular Lymphoma1 trial

References

Drug Info

Quick Facts

Related News